Progress Toward Rubella and Congenital Rubella Syndrome Control — South-East Asia Region, 2000–2016

Details

• Journal Article:
  Morbidity and Mortality Weekly Report (MMWR)
• Personal Author:
  Khanal, Sudhir ; Bahl, Sunil ; Sharifuzzaman, Mohammad ; Dhongde, Deepak ; Pattamadilok, Sirima ; Reef, Susan ; Morales, Michelle ; Dabbagh, Alya ; Kretsinger, Katrina ; Patel, Minal
• Description:
  In 2013, the 66th session of the Regional Committee of the World Health Organization (WHO) South-East Asia Region (SEAR)* adopted the goal of elimination of measles and control| of rubella and Congenital rubella syndrome (CRS) by 2020 (1). Rubella is the leading vaccine-preventable cause of birth defects. Although rubella typically causes a mild fever and rash in children and adults, rubella Virus infection during pregnancy, especially during the first trimester, can result in miscarriage, fetal death, or a constellation of Congenital malformations known as CRS, commonly including visual, auditory, and/or cardiac defects, and developmental delay (2). Rubella and CRS control capitalizes on the momentum created by pursuing measles elimination because the efforts are programmatically linked. Rubella-containing vaccine (RCV) is administered as a combined measles and rubella vaccine, and rubella cases are detected through case-based Surveillance for measles or fever and rash illness (3). This report summarizes progress toward rubella and CRS control in SEAR during 2000-2016. Estimated coverage with a first RCV dose (RCV1) increased from 3% of the birth cohort in 2000 to 15% in 2016 because of RCV introduction in six countries. RCV1 coverage is expected to increase rapidly with the phased introduction of RCV in India and Indonesia beginning in 2017; these countries are home to 83% of the SEAR birth cohort. During 2000-2016, approximately 83 million persons were vaccinated through 13 supplemental immunization activities (SIAs) conducted in eight countries. During 2010-2016, reported rubella incidence decreased by 37%, from 8.6 to 5.4 cases per 1 million population, and four countries (Bangladesh, Maldives, Sri Lanka, and Thailand) reported a decrease in incidence of ≥95% since 2010. To achieve rubella and CRS control in SEAR, sustained investment to increase routine RCV coverage, periodic high-quality SIAs to close immunity gaps, and strengthened rubella and CRS Surveillance are needed.
• Subjects:
  Adolescent Adult Child Child, Preschool Disease Outbreaks Female Full Report Genotype Humans Immunization Schedule Incidence Infant Male Population Surveillance Rubella Rubella Syndrome, Congenital Rubella Vaccine Rubella Virus Vaccination Coverage Young Adult

  More +
• Source:
  MMWR Morbidity Mortal Weekly Rep. 67(21):602-606.
• Series:
  Weekly Report: Morbidity and Mortality Weekly Report (MMWR)
• DOI:
  http://dx.doi.org/10.15585/mmwr.mm6721a3
• ISSN:
  0149-2195 (print) ; 1545-861X (digital)
• Pubmed ID:
  29851943
• Pubmed Central ID:
  PMC6038900
• Document Type:
  Journal Article
• Place as Subject:
  Asia, Southeastern
• Pages in Document:
  5 pdf pages
• Volume:
  67
• Issue:
  21
• Collection(s):
  Morbidity and Mortality Weekly Report (MMWR)
• Main Document Checksum:
  urn:sha-512:0a70360c5b46ab72661c53a6a8d9704ac8c83bb789bd3ea9a88b686b307343f3101391e7ba3087c0d444159d6c16b92b2f6efa5d22e868a2855d6d50c7e63aa6
• Download URL:
  https://stacks.cdc.gov/view/cdc/57355/cdc_57355_DS1.pdf
• File Type:
  [PDF - 121.52 KB ]